GLS (Glutaminase)

Show simple item record

dc.contributor.author Campos-Sandoval, José A. -
dc.contributor.author Martin-Rufián, Mercedes -
dc.contributor.author Márquez, Javier -
dc.date.accessioned 2019-11-05T12:12:19Z
dc.date.available 2019-11-05T12:12:19Z
dc.date.issued 2019 -
dc.identifier.citation José A., Campos-Sandoval ; Mercedes, Martin-Rufián ; Javier, Márquez. GLS (Glutaminase). Atlas of Genetics and Cytogenetics in Oncology and Haematology, 2019, 9, p. 256-268 -
dc.identifier.issn 1768-3262
dc.identifier.uri http://hdl.handle.net/2042/70527
dc.description.abstract After metabolic reprogramming, many cancer cells become glutamine addicted, that is, they depend on a high consumption of this amino acid for their survival and proliferation. Glutaminase catalyzes the stoichiometric conversion of L-glutamine to L-glutamate and ammonium ions, the first step of glutaminolysis. GLS gene encodes two isoforms, known as kidney-type glutaminase (KGA) and glutaminase C (GAC). Upregulation of GLS is a common feature of many tumors and, in recent years, this enzyme and its interacting partners have attracted much attention as potential new targets for cancer therapy. Considerable effort is being devoted towards the development of small-molecule inhibitors of GLS. en
dc.language.iso en -
dc.publisher ARMGHM - Atlas Génétique des Cancers -
dc.relation Atlas of Genetics and Cytogenetics in Oncology and Haematology ; http://AtlasGeneticsOncology.org/Genes/GLSID45600ch2q32.html -
dc.relation.ispartofseries Atlas of Genetics and Cytogenetics in Oncology and Haematology en
dc.rights Open access resource - terms and conditions : http://irevues.inist.fr/utilisation -
dc.subject Glutaminase en
dc.subject glutamine addiction en
dc.subject anticancer therapy en
dc.subject BPTES en
dc.subject CB-839 en
dc.subject compound 968 en
dc.subject breast cancer en
dc.subject colorectal cancer en
dc.subject glioblastoma en
dc.subject hepatocellular carcinoma en
dc.subject leukemia en
dc.subject lung cancer en
dc.subject melanoma en
dc.subject ovarian cancer en
dc.subject prostate cancer en
dc.subject.classification Genes Section en
dc.subject.mesh Adult en
dc.subject.mesh Aged en
dc.subject.mesh Animals en
dc.subject.mesh Big Data en
dc.subject.mesh CRISPR-Cas Systems en
dc.subject.mesh Carcinoma, Hepatocellular/drug therapy/genetics/metabolism/*pathology en
dc.subject.mesh Cell Line, Tumor en
dc.subject.mesh Female en
dc.subject.mesh Gene Expression Regulation, Neoplastic en
dc.subject.mesh Gene Knockout Techniques en
dc.subject.mesh Glutaminase/antagonists & inhibitors/*genetics/*metabolism en
dc.subject.mesh Hep G2 Cells en
dc.subject.mesh Humans en
dc.subject.mesh Liver Neoplasms/drug therapy/genetics/metabolism/*pathology en
dc.subject.mesh Male en
dc.subject.mesh Mice en
dc.subject.mesh Middle Aged en
dc.subject.mesh Neoplasm Transplantation en
dc.subject.mesh Neoplastic Stem Cells/drug effects/*metabolism en
dc.subject.mesh Prognosis en
dc.subject.mesh Reactive Oxygen Species/*metabolism en
dc.title GLS (Glutaminase) en
dc.type Article -
dc.contributor.affiliation Department of Molecular Biology and Biochemistry, Faculty of Sciences, Campus de Teatinos, University of Málaga, 29071 Málaga, Spain -
dc.contributor.affiliation Instituto de Investigación Biomédica de Málaga (IBIMA), 29010 Málaga, Spain -
dc.identifier.doi https://doi.org/10.4267/2042/70527


Files in this item

PDF 02-2019-GLSID45600ch2q32.pdf 428.8Kb

This item appears in the following Collection(s)

Show simple item record





Advanced Search